Search
Search Results
##search.searchResults.foundPlural##
-
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1820PDF: 1187HTML: 258 -
HIGH SERUM ERYTHROPOIETIN AND FERRITIN LEVELS ASSOCIATED WITH ANEMIA RESPONSE IN MALIGNANT LYMPHOMA
1614PDF: 812HTML: 2864cover letter: 211 -
-
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3713PDF: 912HTML: 6728 -
CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
3285PDF: 916HTML: 1548Fig.1 CHL-R paper: 228Fig 2 CHL-R paper: 252 -
EVALUATION OF THE PLASMA MICRO RNA EXPRESSION LEVELS IN SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
1421PDF: 708HTML: 1103Untitled: 191Untitled: 156Untitled: 140Untitled: 160Untitled: 169 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4096Suppl. Files: 1176PDF: 1099Html: 192 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1243PDF: 937HTML: 293 -
-
THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE
6391PDF: 2159HTML: 14036Untitled: 209figure: 193 -
FIRST-PHASE INSULIN RESPONSE (FPIR) TO INTRAVENOUS GLUCOSE TOLERANCE TEST (IVGTT), INSULIN SENSITIVITY AND LONG-TERM FOLLOW-UP IN TRANSFUSION-DEPENDENT BETA-THALASSEMIA (TDT) NORMOGLYCEMIC PATIENTS WITH REDUCED INSULIN SECRETION TO ORAL GLUCOSE TOLERANCE TEST: A PILOT STUDY. The function of the endocrine pancreas in transfusion-dependent ?-thalassemia
7462PDF: 578HTML: 238 -
Acquired Hemophilia A successfully treated with rituximab
2105PDF: 1164HTML: 1460Figure 1: 199 -
-
LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.
3762PDF: 1125HTML: 2445Figure 1: 215 -
Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients
974PDF: 576HTML: 2202Cover Letter: 201 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2510HTML: 287PDF: 916 -
PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome
1172PDF: 790HTML: 335 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3386PDF: 1382HTML: 2683 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1312PDF: 907HTML: 325 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1286PDF: 1087HTML: 219 -
CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia
1108PDF: 1358HTML: 115 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
3992PDF: 1134HTML: 463 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2824PDF: 1145HTML: 3299 -
-
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1364PDF: 441HTML: 106 -
MUTATIONAL PROFILES OF F8 AND F9 IN A COHORT OF HAEMOPHILIA A AND HAEMOPHILIA B PATIENTS IN THE MULTI-ETHNIC MALAYSIAN POPULATION
2073PDF: 1072HTML: 765Figure 1: 168Figure 2: 187







